One of the strictest laws in the EU: even small personal possession is a criminal offense (6 months–3 years). There is effectively no medical cannabis flower program — only Sativex is approved.
Slovakia has one of the strictest cannabis regimes in the European Union. All possession, sale, and cultivation of cannabis remain illegal, and even a small amount for personal use is a criminal offense under Section 171 of the Criminal Code, carrying a sentence of 6 months to 3 years, with aggravated cases (such as near a school, or involving a minor) reaching up to 5 years; some sources describe maximum exposure in certain aggravated scenarios as high as 8 years depending on the specific charge brought (see MyCannabis and CMS Expert Guides). There is no decriminalized personal-use threshold — unlike neighboring Czech Republic, even a single joint can trigger criminal prosecution rather than a civil fine.
Slovakia does not have a functioning medical cannabis program in the sense of prescribable flower or extracts. In 2023, parliament approved a framework permitting cannabidiol-rich preparations, but this did not create a system allowing doctors to prescribe cannabis flower or THC-containing extracts, and broader medical cannabis products — oils, tinctures, or other non-pharmaceutical preparations containing THC or CBD for therapeutic use — remain prohibited under national law (see CannIntelligence). CBD itself is not currently permitted for internal/ingestible use; the Slovak Ministry of Health has indicated it expects CBD-related business development mainly in cosmetics rather than ingestible products. Earlier reporting has indicated that the nabiximols oromucosal spray Sativex is available as an approved pharmaceutical product distinct from this CBD framework; we were not able to independently reconfirm current Sativex availability in this round of research, so this detail should be treated as based on prior reporting rather than freshly verified.
We found no official Slovak government statement addressing foreign medical cannabis patients traveling with their own prescribed cannabis. Given the severity of Slovak criminal penalties for any cannabis possession and the near-absence of a functioning domestic medical cannabis program, there is no visible legal basis for assuming a travel exception exists, and no evidence that an Article 75-style Schengen medicine certificate is recognized for cannabis-based products in Slovakia. Patients should treat carrying any cannabis-based medication — flower, oil, or extract — into Slovakia as a real and serious legal risk, not a gray area, regardless of documentation from another country.
As of 2026, there is no published government plan to broaden Slovakia's medical cannabis framework beyond the narrow 2023 CBD-rich preparation rules, and CBD for internal consumption remains outside the legal framework. Slovak drug policy continues to be markedly more restrictive than that of its immediate neighbors, including both the Czech Republic (full personal-use legalization from January 2026) and Poland (an established medical program), leaving Slovakia something of an outlier in the region.